May 9, 2018

Going Viral

How a new factory-in-a-box is helping scale up manufacturing of viral vector-based therapies to reach more patients.

Manufacturing viral vector-based therapies such as vaccines and gene and cell therapies is complex, but a new manufacturing solution helps solve those challenges. The new KUBio BSL-2 solution for viral vector-based therapeutics, including oncolytic vaccines and cell and gene therapies allows manufacturers to quickly build a ready-to-run, prefabricated modular manufacturing facility for these therapies, and then rapidly add production capacity to meet demand.

Tags: bioprocessing viral vectors, viral vector manufacturing